
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics is a promising investment opportunity due to its strong focus on addressing unmet medical needs in chronic neuropathic pain and neuropathy. The company has a diverse product pipeline with potential milestones and partnerships in the near future, including the initiation of SP16 clinical trials in 3Q26 and discussions with potential partners for legacy assets and development partnerships for Halneuron, which could lead to significant upside for the stock. Additionally, the company has a solid financial position with a projected 12-month price target of $12.00 per share, derived from a risk-adjusted net present value analysis of $429M, supported by expected revenues through 2033.
Bears say
Dogwood Therapeutics is facing numerous financial challenges, including a lack of revenue, pre-clinical stages of development, and a reliance on licensing agreements for funding and commercialization. Despite the potential of their pipeline, the recent licensing of their anti-viral assets to PridCor presents minimal short-term impact and the lack of upfront payments or near-term clinical milestones creates uncertainties for future financial stability. The company's focus on Halneuron overshadows the potential of their anti-viral assets, which may lead to missed opportunities for revenue and growth in the long-term.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares